Educated Patient® Lung Cancer Summit: March 6, 2021

Libtayo survival data, a rare positive osteosarcoma trial and new ADCs for breast, lung and stomach cancers are among ESMO 2026 abstracts to watch.

Depending on dose, firmonertinib shrank tumors in 43% to 68% of patients as a first treatment for EGFR PACC-mutant lung cancer in the phase 1b FURTHER trial.

U.S. counties where more residents had medical debt in collections had higher rates of late-stage lung, head and neck, colorectal and several other cancers, according to a study of 2,958 counties published in October 2026 in JAMA Network Open.

Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.